Vor Biopharma Inc.

Biological Products, (No Diagnostic Substances)

VOR Pharmaceuticals & Biotechnology People in Pharmaceuticals & Biotechnology SEC CIK 0001817229 ↗

Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.

Market capitalisation
$1.21B
59,162,294 shares Covers every share class this company has on file.
Insiders on file
8
people who have filed Form 3, 4 or 5 naming this issuer
Value of insider-held stock
$91.44M
from the holdings reported on Forms 3/4/5; this figure has no separate as-of date on file
Insider-held share of market cap
7.57%
insider-held value divided by market capitalisation

What Vor Biopharma Inc. reports

Revenue and net income below are for fiscal period FY2025, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.

Revenue
No revenue figure: this company’s filings tag profit, but no single revenue total.
Net income
-$695.98M
FY2025 a loss for the period, from this company’s own annual XBRL filings to the SEC
Employees
76
Yahoo Finance
Why the revenue box is blank

US GAAP has no one “total revenue” tag that every filer uses. A bank reports interest and dividend income separately from non-interest income; closed-end funds, blank-cheque companies and some property trusts report the same way; and a company that has not sold anything yet — a drug developer still in trials, for instance — files no revenue at all. Adding two differently defined income lines together would produce a number that appears in no filing, so we publish a revenue figure only where the filing tags one annual, US-dollar revenue fact we can point at. A blank here means no such tag, not that we failed to look.

Where the employee count comes from

Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.

Insiders at Vor Biopharma Inc.

Shares is what each person last reported holding here.

Everyone below has filed at least one insider report against this company.

Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.

Rows are grouped by the role each person reports.

The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.

People who file insider reports against Vor Biopharma Inc..
Insider Reported role Shares Value Last action
Officers 6
Qing Che Zuraw Other Executive 937,080 $23.47M A Grant or award Jul 17, 2025 position reported
Tirtha Chakraborty Other Executive 217,416 $5.45M F Shares withheld for taxes May 6, 2025 position reported
Nathan D Jorgensen CFO 189,403 $4.74M F Shares withheld for taxes May 6, 2024 position reported
Eyal C Attar Other Executive 126,625 $3.17M S Open-market sale Feb 13, 2025 position reported
Han Wook Choi CFO 51,280 $1.28M F Shares withheld for taxes May 1, 2025 position reported
Amy Quinlan VP 50,312 $1.26M F Shares withheld for taxes Nov 6, 2024 position reported
Officers who also sit on the board 1
Robert Ang CEO 911,318 $22.83M F Shares withheld for taxes May 6, 2025 position reported
Directors 1
Reid Hoffman Reid Hoffman Board Member 1,166,909 $29.23M S Open-market sale Oct 21, 2025 position reported

Recent insider transactions

Of the 92 rows we hold, 1 are open-market purchases (P) and 46 open-market sales (S) — the only codes we count as buying or selling.

The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.

A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.

Insider transactions disclosed to the SEC for Vor Biopharma Inc., newest first, each with the filing behind it.
Date Insider Transaction Shares Price Value Filing
Oct 21, 2025 Reid Hoffman S Open-market sale 200 $30.08 $6.0K SEC filing ↗
Oct 20, 2025 Reid Hoffman S Open-market sale 11,616 $30.05 $349.1K SEC filing ↗
Oct 17, 2025 Reid Hoffman S Open-market sale 24,689 $30.22 $746.1K SEC filing ↗
Oct 17, 2025 Reid Hoffman S Open-market sale 1,028 $31.00 $31.9K SEC filing ↗
Oct 16, 2025 Reid Hoffman S Open-market sale 2,021 $30.45 $61.5K SEC filing ↗
Oct 15, 2025 Reid Hoffman S Open-market sale 14,851 $31.05 $461.1K SEC filing ↗
Oct 15, 2025 Reid Hoffman S Open-market sale 48,910 $32.05 $1.57M SEC filing ↗
Oct 15, 2025 Reid Hoffman S Open-market sale 7,894 $32.77 $258.7K SEC filing ↗
Oct 14, 2025 Reid Hoffman S Open-market sale 33,668 $30.32 $1.02M SEC filing ↗
Oct 13, 2025 Reid Hoffman S Open-market sale 19,672 $32.36 $636.6K SEC filing ↗
Oct 13, 2025 Reid Hoffman S Open-market sale 2,334 $33.09 $77.2K SEC filing ↗
Oct 10, 2025 Reid Hoffman S Open-market sale 40,983 $30.97 $1.27M SEC filing ↗
Oct 9, 2025 Reid Hoffman S Open-market sale 33,842 $31.92 $1.08M SEC filing ↗
Oct 9, 2025 Reid Hoffman S Open-market sale 15,042 $32.41 $487.5K SEC filing ↗
Oct 8, 2025 Reid Hoffman S Open-market sale 60,926 $33.75 $2.06M SEC filing ↗
Oct 8, 2025 Reid Hoffman S Open-market sale 14,336 $34.34 $492.3K SEC filing ↗
Oct 7, 2025 Reid Hoffman S Open-market sale 27,624 $33.84 $934.8K SEC filing ↗
Oct 6, 2025 Reid Hoffman S Open-market sale 34,847 $37.12 $1.29M SEC filing ↗
Oct 6, 2025 Reid Hoffman S Open-market sale 17,760 $36.00 $639.4K SEC filing ↗
Oct 6, 2025 Reid Hoffman S Open-market sale 18,156 $37.77 $685.8K SEC filing ↗
Oct 3, 2025 Reid Hoffman S Open-market sale 4,701 $38.14 $179.3K SEC filing ↗
Oct 3, 2025 Reid Hoffman S Open-market sale 3,200 $37.37 $119.6K SEC filing ↗
Oct 2, 2025 Reid Hoffman S Open-market sale 4,937 $37.21 $183.7K SEC filing ↗
Oct 2, 2025 Reid Hoffman S Open-market sale 1,513 $38.38 $58.1K SEC filing ↗
Oct 2, 2025 Reid Hoffman S Open-market sale 5,300 $42.32 $224.3K SEC filing ↗

From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.

What a Form 4 is

The report an officer, director or large shareholder must file after trading their own company’s stock.

Corporate ownership links — 4 filers hold a position

Who owns Vor Biopharma Inc.

Each row is one filer naming this company.

Funds, trusts and other companies file the same ownership forms that executives do. Everything below is taken from those filings, with the position exactly as the filing states it.

Do not add these figures together. 4 of the positions below were reported on filings shared by several filers at once.

Why the same shares appear twice

On a joint filing every named filer is listed against the whole position, so the same block of stock appears under each name. Those rows are marked joint.

Filers holding a position in Vor Biopharma Inc.

Funds, trusts and companies that disclose an ownership position in Vor Biopharma Inc..
Owner Reported role Shares Filed
RA Capital Healthcare Fund LP Director,Other,TenPercentOwner 5,404,998 joint
RA CAPITAL MANAGEMENT, L.P. Director,Other,TenPercentOwner 5,404,998 joint
RA Capital Nexus Fund, L.P. Director,TenPercentOwner 1,401,226 joint
Reprogrammed Interchange LLC TenPercentOwner 1,166,909 joint

See the full ownership map — every entity that files as an owner of a US public company.

Think a number here is wrong? Open the linked filing and compare — how to report it.

Sources and technical notes

Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.

Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from Vor Biopharma Inc.’s own filings and multiplied by our closing price. Full method.

What that share count means

the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.

We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from Vor Biopharma Inc.’s own SEC filings multiplied by the closing price we hold for the same stock.